EOquin (Apaziquone) by Spectrum Pharmaceuticals, Inc.

| Register (free)

A synthetic bio-reductive prodrug that is being investigated in the treatment of non-invasive bladder cancer.

More Info about EOquin (Apaziquone)

Drug Type:	Cancer
Current FDA Status:	Unknown
Current Drug Phase:	Phase 3

No comments found.

Add Comment

In order to write a comment you must first login.

Add Comment

Disclaimer: FDACal.com is not associated with U.S Food and Drug Administration. FDACal.com is not a financial advisor, and does not recommend the purchase of any stock or advise on the suitability of any trade or investment. Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing. It is also important to know that an event date can be altered at anytime based on market changes.

Developed by Media Riot

Things To Do: Create An Account; Create Company Profile; Create Drug Profile; Browse Companies & Drugs; FDA Calendar; FDA Calendar for 2011

About FDACal.Com & More: About FDACal; Contact Us; Testimonials; Useful Links; Our Disclaimer; Updates and Roadmap; Follow @fdacal on Twitter; FDACal on Facebook

Most Browsed Companies: Cell Therapeutics, Inc.; Dendreon Corporation; InterMune, Inc.; Alexza Pharmaceuticals, Inc.; Spectrum Pharmaceuticals, Inc.; Vivus, Inc.; Orexigen Therapeutics, Inc.; MannKind Corporation; Arena Pharmaceuticals Inc.; CombinatoRx, Incorporated

Most Browsed Drugs: AZ-004; Pirfenidone/Esbriet; Pixantrone; Contrave; Zenvia; Lorcaserin; Vimovo; Qnexa; Tesamorelin; Provenge